Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,903 people get AEZS articles and Market Currents by email alert.
Get email alerts on AEZS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire (Wed, 7:30AM)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
Æterna Zentaris Inc. - Shareholder/Analyst CallThu, Apr 25
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
PR Newswire (Mar 21, 2013)
-
-
Stock Watch Wednesday, 20 March 2013VFC's Stock House • Wed, Mar 20 -
PR Newswire (Mar 13, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
A Dismal 2012 May Make For A Good Entry Now For AEterna ZentarisChemistfrog • Tue, Nov 13, 2012
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Stock Watch Wednesday, 20 March 2013VFC's Stock House • Wed, Mar 20
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Æterna Zentaris Inc. - Shareholder/Analyst CallThu, Apr 25
-
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in TorontoPR Newswire (Wed, 7:30AM)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 7, 2013)
-
PR Newswire (Apr 17, 2013)
-
PR Newswire (Apr 15, 2013)
-
PR Newswire (Mar 21, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Feb 20, 2013)
-
at CNBC.com (Jan 9, 2013)
-
PR Newswire (Dec 4, 2012)
-
PR Newswire (Nov 26, 2012)
AEZS vs. ETF Alternatives
Company Description
Currently, there's no company description for AEZS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 8, 4:02 PM Aeterna Zentaris (AEZS +1.6%) moves up after posting a better than expected Q1. Zacks upgraded the shares to Outperform from Neutral on the back of the report with a price target of $2.10. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, April 17, 12:44 PM AEterna Zentaris (AEZS -2%) says it's agreed to transfer rights and grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA. It will receive a one-time payment of about $3.2M for the transaction, as well as certain other payments to execute a 36-month transitional services agreement to provide various transition services to assist Merck KGaA in assuming responsibility for manufacturing. Comment! [Healthcare, On the Move]
-
Thursday, April 11, 9:10 AM
Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move] - Wednesday, April 10, 7:51 PM Aeterna Zentaris (AEZS) issues updated proof-of-concept results for its tumor treating Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138. The company says results showed the compounds have high potential for the treatment of luteinizing hormone-releasing hormone receptor positive tumors, particularly in human ovarian and endometrial cancer xenograft models. Shares +19% AH. Comment! [Healthcare, On the Move]
-
Wednesday, April 10, 6:15 PM
After-hours top gainers, as of 5:45 p.m.: AEZS +29%. ZUMZ +10%. PCYG +4%. BLK +4%. MDU +3%.
After-hours top losers: FTNT -15%. APOG -7%. EQIX -4%. FIRE -4%. YUM -3%. Comment! [On the Move] -
Monday, March 11, 12:56 PM
Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%. Comment! [On the Move] - Monday, March 11, 12:13 PM Shares of Aetna Zentaris (AEZS) continue to plunge since their resumption of trading, now down 29% at $1.86 after an independent data safety monitoring board recommended discontinuing ongoing Phase 3 studies of perifosine. Comment! [Healthcare, On the Move]
- Monday, March 11, 11:47 AM Aeterna Zentaris (AEZS) resumes trading -10%. Comment! [Healthcare, On the Move]
- Monday, March 11, 11:29 AM Shares of Aeterna Zentaris (AEZS -1.9%) remain halted after the company says an independent Data Safety Monitoring Board has recommended discontinuing ongoing Phase 3 studies comparing the efficacy and safety of perifosine in patients with relapsed or relapsed/refractory multiple myeloma. Based on its analysis, the DSMB reported that it was highly unlikely the study would achieve a significant difference in its primary endpoint. Comment! [Healthcare, On the Move]
- Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]
-
Tuesday, January 29, 12:45 PM
Midday top 10 gainers: MLNK +32%. KERX +30%. SOMH +25%. VTUS +24%. MHH +14%. SWIR +14%. AEZS +11%. CNIT +11%. IBCP +10%. SSBI +10%.
Midday top 10 Losers: OXF -31%. ANAC -21%. VMW -20%. SANM -18%. OCZ -18%. LXK -15%. CTC -13%. GIG -12%. NTGR -11%. SHIP -11%. Comment! [On the Move] -
Friday, December 28, 2012, 12:45 PM
Midday top 10 gainers: TRIT +57%. AMPL +22%. AEZS +16%. LDK +13%. SOQ +13%. YONG +13%. PAMT +11%. ABCD +11%. MNOV +10%. MNGA +10%.
Midday top 10 Losers: ISSC -31%. BAGL -26%. FSGI -15%. PLBC -14%. BOSC -13%. OMER -11%. AMBO -9%. MOC -8%. SMED -8%. PRIS -8%. Comment! [On the Move] - Friday, December 28, 2012, 11:05 AM Shares of Aeterna (AEZS) are now soaring, up over 18% on the back of earlier reports that it's reached an agreement with the FDA on a Special Protocol Assessment for Phase 3 trials of its endometrial cancer treatment doxorubicin eptide conjugate, or AEZS-108. The company says the agreement provides it with "a clearly defined development and regulatory pathway." Comment! [Healthcare, On the Move]
- Friday, December 28, 2012, 9:27 AM AEterna Zentaris (AEZS) +4.8% premarket after announcing the FDA supports a phase 3 trial of its drug AEZS-108, a potential treatment for endometrial cancer. A "special protocol assessment" agreement says the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission. Comment! [Healthcare, On the Move]
- Friday, December 28, 2012, 9:10 AM Premarket gainers: AEZS +5%. Comment! [On the Move]
- Tuesday, December 11, 2012, 11:09 AM Aeterna Zentaris (AEZS +2.8%) trades up after reporting that final Phase II data demonstrated that its oral AKT inhibitor perifosine, when combined with sorafenib, was well tolerated by heavily pretreated lymphoma patients. Furthermore, promising clinical response activity was observed in patients with classical Hodgkin Lymphoma, suggesting that this subgroup could represent a target population for future studies. Comment! [Healthcare, On the Move]
-
Ryan Mallory
Fuinhaz Setups for April 11 2013 | $AEZS $AMRS $ASML $CETV $GRPN $NFLX $VOD $ZNGA | http://bit.ly/YNtwJP - View all 0 replies
-
VFC's Stock House
$AEZS - Many gave Perifisone no chance after $KERX failure... Monday action likely the result of opportune shorts. http://bit.ly/cAHZ42 - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
-
- View all 0 replies
-
- View all 2 replies
-
-
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
-
- View all 1 replies
-
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
-
smokeyRose
Bought CLNE should have done that yesterday! sold a couple losers KERX & AEZS bunch of losers!!!! hope after pres speaks CLNE will JUMP!! - View all 0 replies
-
- View all 0 replies
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
-
- View all 2 replies
-
-
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
-
- View all 1 replies
-
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
-
VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY - View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 10 replies
-
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not? -
-
The Scientist
KERX should not have given away perifosine rights to AEZS. Strongest data is for r/r MM. Study headed by Dr. Richardson at Dana-Farber - View all 1 replies
-
The Scientist: Dr Richardson director of MM at Dana-F. He is not dumb enough to waste his time-effort if perifosine had NO possible chance of working
-
- View all 1 replies
-
-
- View all 2 replies
-
hotnutsjesus: lol, it went up because of the Jeremy Richards article and then the validity of the article/author was questioned. Looks kinda like a pump -
-
- View all 3 replies
-
sstonerm3: MovA, I added to my COSWF last October under $21. Getting close to time to get some more me thinks. -
-
Michael Bryant
AEterna Zentaris' (AEZS) chart shows impressive support/resistance. Just from chart, one can guess stock will go up http://yhoo.it/yrhLvO - View all 2 replies
-
Funkengruven: It's been awhile... hopefully good things come to those that wait! -
-
- View all 1 replies
-
Andreas Braun: the more effective perifosine is the longer it takes to come to the 360th event
-
The Scientist
If AEZS's perifosine had absolutely no effect or was detrimental to colon CA patients, the DSMB would have stopped the trial in August. - View all 1 replies
-
-
- View all 1 replies
-